The Dual-Targeting Activity of the Metabolite Substrate of Para-amino Salicyclic Acid in the Mycobacterial Folate Pathway: Atomistic and Structural Perspectives.
Aminosalicylic Acid
/ chemistry
Antitubercular Agents
/ chemistry
Binding Sites
Drug Design
Folic Acid
/ metabolism
Folic Acid Antagonists
/ chemistry
Models, Molecular
Molecular Conformation
Mycobacterium tuberculosis
/ enzymology
Tetrahydrofolate Dehydrogenase
/ metabolism
Thymidylate Synthase
/ antagonists & inhibitors
Dihydrofolate reductase
Flavin-dependent thymidine synthase
Folate biosynthetic pathway
Molecular dynamics simulation
Mycobacterium tuberculosis
Tuberculosis
Journal
The protein journal
ISSN: 1875-8355
Titre abrégé: Protein J
Pays: Netherlands
ID NLM: 101212092
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
23
2
2020
medline:
20
11
2020
entrez:
23
2
2020
Statut:
ppublish
Résumé
Therapeutic targeting of folate biosynthetic pathway has recently been explored as a viable strategy in the treatment of tuberculosis. The bioactive metabolite substrate of Para-amino salicyclic acid (PAS-M) reportedly dual-targets dihydrofolate reductase (DHFR) and flavin-dependent thymidylate synthase (FDTS), two essential enzymes in folate biosynthetic pathway. However, the molecular mechanisms and structural dynamics of this dual inhibitory activity of the PAS-M remain elusive. Molecular dynamics simulations revealed that binding of PAS-M towards DHFR is characterized by a recurrence of strong conventional hydrogen bond interactions between a peculiar DHFR binding site residue (Asp27) and the 2-amino-decahydropteridin-4-ol group of PAS-M. Similarly, the binding of PAS-M towards FDTS also involved consistent strong conventional hydrogen bond interactions between some specific residues (Tyr101, Arg172, Thr4, Gln103, Arg87 and Gln106) and, the 2-amino-decahydropteridin-4-ol group, thus establishing the cruciality of the group. Structural dynamics of the bound complexes of both enzymes revealed that, upon binding, PAS-M is anchored at the entrance of hydrophobic pockets by strong hydrogen bond interactions while the rest of the structure gains access to deeper hydrophobic residues to engage in favorable interactions. Further analysis of atomistic changes of both enzymes showed increased C-α atom deviations as well as an increase C-α atoms radius of gyration consistent with structural disorientations. These conformational changes possibly interfered with the biological functions of the enzymes and hence their inhibition as experimentally reported. Structural Insights provided could open up a novel paradigm of structure-based design of multi-targeting inhibitors of biological targets in the folate biosynthetic pathway toward tuberculosis therapy.
Identifiants
pubmed: 32086691
doi: 10.1007/s10930-020-09885-1
pii: 10.1007/s10930-020-09885-1
doi:
Substances chimiques
Antitubercular Agents
0
Folic Acid Antagonists
0
Aminosalicylic Acid
5B2658E0N2
Folic Acid
935E97BOY8
Tetrahydrofolate Dehydrogenase
EC 1.5.1.3
Thymidylate Synthase
EC 2.1.1.45
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106-117Références
Comput Biol Med. 2018 Jul 1;98:168-177
pubmed: 29860210
J Mol Biol. 2005 Oct 7;352(5):1091-104
pubmed: 16139296
Front Pharmacol. 2017 Sep 26;8:689
pubmed: 29033842
Future Med Chem. 2018 Jul 1;10(14):1665-1675
pubmed: 29957065
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Cell Chem Biol. 2019 Jun 20;26(6):781-791.e6
pubmed: 30930162
Curr Treat Options Neurol. 2018 Feb 28;20(3):5
pubmed: 29492737
Arch Toxicol. 2016 Jul;90(7):1585-604
pubmed: 27161440
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7
pubmed: 12569078
J Mol Biol. 2016 Nov 6;428(22):4559-4571
pubmed: 27663270
N Engl J Med. 1994 Apr 28;330(17):1179-84
pubmed: 8139628
FEBS J. 2015 Oct;282(20):3899-917
pubmed: 26074325
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
Br Med Bull. 2005 Jun 14;73-74:17-24
pubmed: 15956357
J Mol Biol. 1994 Jan 14;235(2):625-34
pubmed: 8289285
J Chem Inf Model. 2014 May 27;54(5):1552
pubmed: 24702057
Comput Biol Chem. 2018 Apr;73:49-56
pubmed: 29427909
Front Pharmacol. 2018 Aug 22;9:923
pubmed: 30186166
N Engl J Med. 2012 Jun 7;366(23):2161-70
pubmed: 22670902
Lancet. 2014 Apr 5;383(9924):1230-9
pubmed: 24439237
Curr Protoc Protein Sci. 2007 Nov;Chapter 2:Unit 2.9
pubmed: 18429317
Mol Microbiol. 2004 Jul;53(1):275-82
pubmed: 15225321
Antimicrob Agents Chemother. 2015 Sep;59(9):5097-106
pubmed: 26033719
J Chem Theory Comput. 2013 Jul 9;9(7):3084-95
pubmed: 26583988
J Phys Chem B. 2014 Jun 19;118(24):6526-30
pubmed: 24655018
Phys Rev A Gen Phys. 1986 May;33(5):3628-3631
pubmed: 9897103
Lancet. 1974 Aug 3;2(7875):237-40
pubmed: 4135686
Cold Spring Harb Perspect Med. 2015 Jan 08;5(5):a017822
pubmed: 25573773
Biotechnol Lett. 2017 Dec;39(12):1843-1851
pubmed: 28918491
J Biomol Struct Dyn. 2018 Apr;36(5):1118-1133
pubmed: 28351337
J Chem Inf Model. 2011 Jan 24;51(1):69-82
pubmed: 21117705
J Cell Biochem. 2018 Mar;119(3):2646-2652
pubmed: 29058783
Mol Inform. 2012 Feb;31(2):114-22
pubmed: 27476956
J Am Chem Soc. 2010 Aug 4;132(30):10330-7
pubmed: 20617834
Infect Dis Clin North Am. 2016 Jun;30(2):509-522
pubmed: 27208770
Nat Rev Microbiol. 2018 Feb;16(2):80-90
pubmed: 29109555
Pulmonology. 2018 Mar - Apr;24(2):86-98
pubmed: 29487031
Biochim Biophys Acta. 2015 May;1850(5):1041-1058
pubmed: 25219455
Clin Pharmacol Ther. 2018 Dec;104(6):1098-1109
pubmed: 30137652
Molecules. 2016 May 20;21(5):
pubmed: 27213314